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www.embomolmed.org EMBOb-Thalassemia is a common monogenic disorder due to mutations in the b-globin
gene and gene therapy, based on autologous transplantation of genetically
corrected haematopoietic stem cells (HSCs), holds the promise to treat patients
lacking a compatible bone marrow (BM) donor. We recently showed correction of
murine b-thalassemia by gene transfer in HSCs with the GLOBE lentiviral vector
(LV), expressing a transcriptionally regulated humanb-globin gene. Here, we report
successful correction of thalassemia major in human cells, by studying a large
cohort of pediatric patients of diverse ethnic origin, carriers of different mutations
and all candidates to BM transplantation. Extensive characterization of BM-derived
CD34þ cells before and following gene transfer shows the achievement of high
frequency of transduction, restoration of haemoglobin A synthesis, rescue from
apoptosis and correction of ineffective erythropoiesis. The procedure does not
significantly affect the differentiating potential and the relative proportion of
haematopoietic progenitors. Analysis of vector integrations shows preferential
targeting of transcriptionally active regions, without bias for cancer-related genes.
Overall, these results provide a solid rationale for a future clinical translation.
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b-Thalassemia is the most frequent monogenic disease with a
global estimated annual birth incidence of 40,000/year, mainly
in the Mediterranean, Middle East and Southern Asia countries
(Modell & Darlison, 2008). The reduced or absent production of
haemoglobin b-chains leads to severe anaemia, requiring
regular blood transfusions (Weatherall & Clegg, 2001). As a
consequence, the increased risk of viral infections and
progressive iron accumulation can cause organs failure. Iron
overload, although reduced by chelation, is not abolished and
vital organs complications still occur affecting quality of life and
representing the principal cause of death (Borgna-Pignatti et al,
2005). At present, the only definitive cure is allogeneic bone
marrow transplantation (BMT), which is, however, available for
a minority of patients. For all patients lacking a suitable bone
marrow (BM) donor, gene therapy, as transplantation of
autologous genetically corrected haematopoietic progenitor/ 2010 EMBO Molecular Medicine 315
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316stem cells, represents an attractive alternative to BMT, since is
not limited by the histocompatibility barrier and does not
require immunosuppression.
The clinical history of the disease and over 20 years of BMT
experience indicates that even a mild correction of the globin
chain imbalance in a fraction of maturing erythroblasts is
sufficient to reduce the morbidity caused by ineffective
erythropoiesis, to improve the clinical management of the
disease and to increase the patients’ life expectancy (Andreani et
al, 2000; Lucarelli & Gaziev, 2008). Long term follow-up of
transplanted patients characterized by persistent mixed chimer-
ism demonstrates that a proportion of normal cells between 15
and 30% is sufficient to provide good quality of life and
transfusion independence (Andreani et al, 2008). Our results in
the murine model of thalassemia indicate that the in vivo
selection of genetically modified erythroblasts results in long-
term correction of the pathology in the presence of a limited
number of transduced haematopoietic stem cells (HSCs) (Miccio
et al, 2008). Therefore, it is predictable that even partial
engraftment of genetically modified stem/progenitor cells
would be therapeutic. So far, one report showed correction of
the thalassemia major phenotype in human cells by a lentiviral
vector (LV) carrying a transcriptionally regulated b-globin gene
flanked by sequences from the chicken b-globin DNaseI
hypersensitive site 4 insulator (cHS4) (Puthenveetil et al,
2004). Disappointingly, the inclusion of a large insert, such as
the 1.2-kb cHS4, in 30-long terminal repeat (LTR), causes
inefficient viral RNA processing thus affecting the production of
high titer viral stocks, required for clinical application (Hanawa
et al, 2009; Urbinati et al, 2009). Recently, the results of the first
trial of gene therapy in one patient were disclosed and the
unexpected observation of a relative dominant haematopoietic
clone, apparently as result of the vector integration, raised a
notion of alarm and caution (Kaiser, 2009; Williams, 2009). At
this time, it is too early to predict if this event would turn out to
be a serious adverse event. Nevertheless, extensive preclinical
studies of biology, efficacy and safety of LV-mediated globin
gene transfer in human cells are mandatory to make a rigorous
evaluation of a predictable successful trial.
CD34þ cells are the target of gene transfer and transplantation
in gene therapy clinical protocols. These cells are a hetero-
genous population covering not only stem cells but also earlier
multipotent progenitors and later lineage-restricted progenitors,
and their relative proportion is related to the haematopoietic
state (steady or stressed) (Bradford et al, 1997; Cheshier et al,
1999), the source (cord blood, BM and mobilized peripheral
blood) (Fritsch et al, 1996; Kinniburgh & Russell) and the age
(van Lochem et al, 2004). Thus, the effect of gene transfer on
progenitors subsets equilibrium has to be evaluated to avoid
skewing to specific cell types. Importantly, the investigation of
the transcriptional response of CD34þ cells to gene transfer
would allow both to predict biological and functional outcome
and to define the best culture conditions to preserve the original
features.
We developed the novel LV GLOBE, harbouring the human
b-globin gene under the control of the minimal promoter and
two elements from the locus control region (LCR), and 2010 EMBO Molecular Medicinedemonstrated its therapeutic efficacy in long-term correction
of murine b-thalassemia (Miccio et al, 2008). In the present
study, we analysed the efficacy and safety of GLOBE-mediated
gene transfer in haematopoietic progenitors isolated from BM
aspirates of a large cohort (n¼ 44) of pediatric patients affected
by b-thalassemia major, characterized by different genetic
mutations. Our study includes an extensive molecular and
biological characterization of the target cells, the optimization of
the transduction protocol and the impact of this procedure on
progenitor cells, the evaluation of gene transfer efficiency and
efficacy and the mapping of proviral integrations in thalassemic
CD34þ cells. To date this represents the most comprehensive
preclinical analysis performed in thalassemia major patients’
cells, whose results will pave the way forward the proposal of
the clinical application of gene therapy using GLOBE LV.RESULTS
Characterization of BM-derived CD34R cells isolated from
patients affected by thalassemia major
Patients affected by b-thalassemia major were enrolled starting
from 2005 in the BM transplantation programme at H.S. Raffaele
(HSR, Milan) and Mediterannean Institute of Hematology (IME
Foundation, Rome). Pre-transplantation BM samples from a
group of patients (n¼ 44, Table 1) were donated for this
research study. The patients were children (age range
2–15 years, median¼ 8, 24 males and 20 females) of different
geographic and ethnic origin, from countries in the Mediterra-
nean area. Twenty-seven were b0-thalassemia patients (carry-
ing the same or different allelic mutations), nine were
homozygous for bþ mutations and eight compound hetero-
zygous for b0 and bþ mutations.
We isolated CD34þ cells from the mononuclear cells (MNC)
fraction of thalassemic BM samples (THAL, n¼ 30), to a yield of
0.22 0.03 106 cells/ml (2.72 0.36%/total MNC) that was
comparable (p> 0.05) to that of normal donor samples (ND,
n¼ 9, 0.16 0.03 106 cells/ml; 1.44 0.24%/total MNC).
Fluorescence-activated cell-sorter scanner (FACS) analysis for
the expression of surface markers, characterizing the multi-
potent, lymphoid and myeloid progenitors (Olweus et al, 1996;
Terstappen et al, 1991; Tjonnfjord et al, 1994) shows that
CD34þCD38CD50þ, CD34þCD10þ and CD34þCD33þ are
2.4 1.1, 61 4 and 35 3.2%, respectively (Fig 2B). Erythroid
hyperplasia is present in thalassemic BM as revealed by the
increased percentages of Glycophorin A (GpA)þ cells in
comparison to the ones observed in normal donor samples
(59 9% of total MNC, n¼ 7 (vs.) 8.2 1.9%, n¼ 4, p< 0.01).
Because of this erythroid expansion, we investigated the
existence of an increased proportion of erythroid committed
progenitors by analyzing CD34þGpAþ, CD34þCD36þ and
CD34þCD71þ cells. Figure 1A shows no significant differences
(p> 0.05) between normal (0.7 0.2%) and thalassemic
(0.9 0.1%) samples in the proportion of CD34þ cells co-
expressing GpA. CD34þCD36þ cells are more abundant in
normal than in thalassemic samples (8.6 1.6% vs. 4.7 1%,
p¼ 0.05), without significant impact on the relative frequency ofEMBO Mol Med 2, 315–328 www.embomolmed.org
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Table 1. Thalassemia major samples
Sample Sex Age Origin Phenotype Mutation Sourcea
THAL 15 F 4 Qwait b0 cod39/cod39 (C> T) IME
THAL 20 M 6 Palest. terr. b0 cod5/cod5 (CT) HSR
THAL 22 M 4 Palest. terr. bþ IVS1-110/IVS1-110 (G> A) HSR
THAL 23 M 5 Palest. terr. bþ IVS1-110/IVS1-110 (G> A) HSR
THAL 27 M 13 Iraq b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 28 F 11 Lebanon b0 cod5/cod5 (CT) HSR
THAL 33 M 11 Iraq bþ IVS1-5/IVS1-5 (G>C) IME
THAL 34 F 11 Iran bþ IVS1-1 (G>A)/cod30 (G>C) IME
THAL 35 M 5 Iraqi Kurd b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 36 F 6 Iraqi Kurd b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 37 F 10 Iraqi Kurd b0 IVS2-1/IVS2-1 (G> A) HSR
THAL 38 F 3 Iraqi Kurd b0 IVS1-1 (G> A)/cod8/9 (þG) HSR
THAL 39 M 9 Iraqi Kurd b0 cod8/9/cod8/9 (þG) HSR
THAL 40 M 13 Iraq b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 41 M 6 Kuwait bþ IVS1-5 (G>C)/cod36/37 (T) IME
THAL 42 F 14 Syria bþ cod39 (C> T)/IVS1-6 (T>C) IME
THAL 43 F 8 Lebanon bþ IVS1-1 (G> A)/Lepore IME
THAL 44 F 10 Kuwait b0 cod44/cod44 (C) IME
THAL 45 F 10 Palest. terr. bþ IVS1-6/IVS1-6 (T>C) HSR
THAL 47 M 12 Lebanon b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 48 M 8 Lebanon bþ cod29/cod29 (C> T) HSR
THAL 49 M 13 Lebanon bþ IVS1-110/IVS1-110 (G> A) HSR
THAL 51 M 15 Lebanon bþ IVS1-110 (G> A)/cod44 (C) IME
THAL 52 M 12 Lebanon bþ IVS1-110/IVS1-110 (G> A) HSR
THAL 53 F 7 Iraqi Kurd b0 cod8/cod8 (AA) HSR
THAL 54 F 3 Iraqi Kurd b0 IVS1-1 (G> A)/cod8/9 (þG) HSR
THAL 55 F 5 Iraqi Kurd b0 IVS1-1 (G> A)/cod8/9 (þG) HSR
THAL 56 F 4 Iraqi Kurd bþ IVS1-6 (T>C)/IVS2-1 (G> A) HSR
THAL 57 M 2 Iraqi Kurd b0 IVS2-1 (G> A)/cod 8 (AA) HSR
THAL 58 M 10 Iraqi Kurd b0 IVS2-1 (G> A)/cod 8 (AA) HSR
THAL 65 F 15 Iraqi Kurd b0 IVS2-1 (G>A)/cod 8/9 (þG) HSR
THAL 66 F 6 Iraq bþ IVS1-110 (G> A)/cod8 (AA) IME
THAL 68 M 3 Maldives b0 cod30/cod30 (G>C) IME
THAL 75 M 9 Iraqi Kurd b0 IVS2-1/IVS2-1 (G> A) HSR
THAL 84 F 3 Egypt b0 IVS1-1/IVS1-1 (G> A) IME
THAL 87 M 8 Egypt bþ IVS1-110/IVS1-110 (G> A) IME
THAL 92 M 8 Syria b0 cod39/cod39 (C> T) HSR
THAL 94 M 5 Syria b0 cod15 (G>A)/cod8 (AA) HSR
THAL 101 M 3 Syria bþ cod39 (C> T)/IVS1-6 (T>C) HSR
THAL 103 F 3 Syria bþ 30/30 (T> T) HSR
THAL 104 F 4 Syria b0 cod39/cod39 (C> T) HSR
THAL 105 F 8 Syria b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 106 M 7 Syria b0 IVS1-1/IVS1-1 (G> A) HSR
THAL 113 M 7 Syria b0 cod8/cod8 (AA) HSR
Palest. terr., Palestinian territories; Iraqi Kurd, Iraqi Kurdistan.
aSource of the BM aspirates: HSR (S.Raffaele Hospital) or IME (Mediterranean Institute of Hematology).clonogenic progenitors (see below). CD71þ cells are signifi-
cantly decreased (p< 0.001, 28 3% vs. 64 4%) in the CD34þ
cell population of thalassemic samples in comparison to normal
samples, suggesting a down-regulation of the transferrin
receptor due to iron overload.
The property of individual early progenitors to give rise to
burst-forming unit erythroid (BFU-E), colony-forming unit
granulo-monocyte (CFU-GM) and colony-forming unit granu-
locyte–erythrocyte–monocyte–megakaryocyte (CFU-GEMM)
colonies was analysed by colony-forming unit (CFU) assay.
An equal number of clonogenic cells (52 5 CFU/1 103 cells
plated) is present in normal (n¼ 12) and thalassemic (n¼ 20)www.embomolmed.org EMBO Mol Med 2, 315–328samples. Percentages of BFU-E, CFU-GM and CFU-GEMM in
patients’ samples are comparable to normal ones (49 4%,
48 4%, 0.9 0.4% vs. 49 5%, 50 5% and 1.2 0.4%,
Fig 1B) indicating no significant alterations associated with the
disease in the phenotype and differentiating potential of CD34þ
cells.
Cytokines treatment of CD34R progenitors induces minor
changes in their phenotype and activity
We optimized a short-term gene transfer procedure consisting of
a pre-stimulation step in the presence of a cocktail of cytokines, 2010 EMBO Molecular Medicine 317
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Figure 1. Characterization of thalassemia major
BM-CD34R cells.
A. Expression of erythroid lineage markers in
BM-CD34þ progenitors: cumulative FACS data of
the percentage of CD34þGpAþ, CD34þCD36þ
and CD34þCD71þ cells plotted for normal (ND,
n¼5, 5 and 3, respectively) and thalassemic
(THAL, n¼17, 8 and 9, respectively) samples.
B. CFU activity of CD34þ cells analysed as total
number of colonies/1000 cells plated and as
proportion of the different type of colonies
(BFU-E, CFU-GM and CFU-GEMM) in ND (n¼ 12)
and THAL (n¼ 20) samples. Values are given as
mean SEM. Asterisks indicate values signifi-
cantly different between groups (p<0.001).
318followed by transduction with the vector stock. In order to
assess the impact of this treatment on CD34þ cells, we compared
progenitors’ phenotype and activity of untreated samples
(THAL, n¼ 20) to the ones of samples activated by cytokines
for 42 h (as duration of pre-stimulation and transduction)
(THAL-act, n¼ 19), or transduced with the vector (THAL-
GLOBE, n¼ 18). No significant difference (p> 0.05) is found in
the number of clonogenic progenitors in THAL, THAL-act and
THAL-GLOBE samples (52 5, 61 5 and 60 5/1000 cells
plated, respectively). Similarly, the proportion of BFU-E
(49 4%, 58 3% and 58 4%), CFU-GM (48 4%,
39 3% and 40 3%) and CFU-GEMM (0.9 0.4%,
0.7 0.2% and 0.5 0.1%) is not significantly modified by
the exposure to cytokines and to vector stock (Fig 2A). Control
experiments performed with normal donor cells reveal no
difference in response to cytokine treatment between patients’
and normal cells (Fig S1 of Supporting Information).
Analysis of the effect of cytokines on progenitor subpopula-
tions shows no significant difference in the proportion of
multipotent progenitors (CD34þCD38CD50þ) before and after
stimulation (2.4 1.1% vs. 2.1 1.4%). Differently, a signifi-
cant decrease in the proportion of lymphoid committed
progenitors CD34þCD10þ (61 4% vs. 38 3%, p< 0.05),
associated with a marked increase in the frequency of myeloid
committed progenitors CD34þCD33þ (35 3% vs. 65 5%,
p< 0.01) is observed in thalassemic cells stimulated with
cytokines (Fig 2B). Importantly, no reduction in the total
number of cells expressing the CD34 marker is evident. In
normal donor samples there is a similar, but less pronounced, 2010 EMBO Molecular Medicineshift in the subpopulations of committed progenitors after
activation (data not shown). Notably, the change in the relative
proportion of committed progenitors, induced by cytokine
exposure, is not associated to a significant alteration in the
number and activity of early progenitor cells, scored by CFU
assay.
Genome expression profiling of thalassemic and normal
CD34R cells and molecular response to cytokine activation
To understand the global impact of cytokine stimulation on the
gene expression programme of CD34þ cells from thalassemic
patients, we determined the expression profile by Affymetrix
microarray analysis on RNA extracted from 20 thalassemic and
22 normal samples, before and after in vitro stimulation. An
unsupervised hierarchical clustering analysis identified two
main branches corresponding to unstimulated and stimulated
samples, indicating that cytokine treatment had the strongest
effect in discriminating between samples, overcoming disease
status (Fig 3A). Indeed, thalassemic and normal samples
clustered together, within each main branch. However, when
five samples derived from pediatric donors were added to the
unstimulated control data set, thalassemic and healthy pediatric
samples clustered together, suggesting that age is a major factor
in driving sample clustering at least in untreated CD34þ cells
(Fig 3B). To define the genes consistently over- or under-
expressed in normal versus thalassemic samples before and after
cytokine treatment, we used a supervised hierarchical ordering
approach. Less than 25 genes (0.1%) were expressed atEMBO Mol Med 2, 315–328 www.embomolmed.org
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Figure 2. Effect of cytokines treatment on
clonogenic activity and progenitors
subpopulations of CD34R cells.
A. CFU activity of CD34þ cells and proportion of the
different type of colonies (BFU-E, CFU-GM and
CFU-GEMM) in thalassemia major samples
untreated (THAL, n¼ 20), activated with
cytokines (THAL-act, n¼ 19) and transduced
with the GLOBE vector (THAL-GLOBE, n¼ 18).
B. Cumulative data from FACS analysis of
multipotent (CD34þCD38CD50þ), lymphoid
(CD34þCD10þ) and myeloid (CD34þCD33þ)
progenitors subpopulations in thalassemia
major untreated (THAL, black bars, n¼ 3, 6 and 6,
respectively) and activated (THAL-act, white
bars, n¼3) samples. Values represent the
mean SEM. Asterisks indicate parameters
significantly different between groups
(p<0.05; p<0.01).significantly different levels in thalassemic versus normal
CD34þ cells in either condition, after Bonferroni correction
(Fig S2 A and B of Supporting Information). Overall, these
results indicate that cytokine treatment induces major changes
in the gene expression programme of CD34þ cells, with no
substantial difference between cells obtained from thalassemic
and healthy donors.
GLOBE transduces at high efficiency CD34R cells from b0 and
bR patients leading to correction of haemoglobin A deficiency
Correction of b-thalassemia by gene therapy requires gene
transfer in stem/progenitor cells and high level of b-globin gene
expression in the differentiated erythroid progeny. To this aim,
we utilized the GLOBE LV, recently described correcting
thalassemia in the murine model (Miccio et al, 2008), and its
derivative containing the woodchuck post-transcriptional
regulatory element. BM-CD34þ cells from 22 thalassemia major
patients (Table 1 of Supporting Information) were transduced
with GLOBE (THAL-GLOBE) or maintained in medium contain-
ing the cytokines only (THAL). Gene transfer efficiency is
variable, as expected from primary cells, but generally high,
ranging from 37 to 95%with a mean value of 65%. Quantitative
PCR (qPCR) performed on DNA extracted from bulk cultures at
day 14 reveals an average vector copy number (VCN)/cell of 1.6
(normalized value 2.6) (Fig 4A). The same analysis, performed
at clonal level in a high number of CFU (n¼ 213) grown in
methylcellulose from transduced CD34þ cells, shows a Poisson-www.embomolmed.org EMBO Mol Med 2, 315–328like distribution, with most of the colonies (83.6%) carrying a
limited VCN (1–4) and a low frequency (2.35%) of colonies with
high VCN (>9) (Fig S3 of Supporting Information). The
association between VCN and the extent of disease correction,
evaluated by FACS and high-performance liquid chromatogra-
phy (HPLC) analysis of haemoglobin A (HbA) production, and
morphological analysis of mature erythroblasts, is indicated for
each sample in the Table S1 of Supporting information.
To assess the efficacy of GLOBE to correct HbA deficiency,
transduced and control cells (n¼ 10) were grown in erythroid
unilineage culture, as in vitro modelling of erythropoiesis. The
representative FACS dot-plot in Fig 4B (left panel) shows
undetectable expression of HbA in a b0 sample (THAL 106) and
residual HbA production, revealed by low mean fluorescence
intensity (MFI), in a bþ sample (THAL 51). In normal erythroid
cultures (ND, n¼ 5), the proportion of HbAþ cells reaches a
maximum of 74% depending on the amount of mature cells.
Following transduction with GLOBE the proportion of HbAþ
cells in cultures from thalassemic patients achieves a level
comparable to the normal ones (44.6 6.7% vs. 53.8 7.2%,
MFI 3170 802AU vs. 2360 429AU) (Fig 4B, right panel). A
statistically significant increase in the amount of HbA
(2076 647AU vs. 1323 429AU, p< 0.05) is observed in
transduced samples from bþ patients (THAL-bþ). At clonal
level, the HbA expression pattern in BFU-Es, isolated from
five independent transduction experiments, is comparable to
that observed in normal colonies (Fig S4 of Supporting
Information). 2010 EMBO Molecular Medicine 319
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Figure 3. Genome expression profiling of
thalassemic CD34R cells and molecular response
to cytokine activation.
A. Unsupervised cluster analysis of transcripts from
thalassemic and normal cells untreated (THAL,
n¼9; ND, n¼ 8) and activated with cytokines
(THAL-act, n¼ 11; ND-act, n¼9).
B. Unsupervised cluster analysis of transcripts from
thalassemic and normal cells, untreated and
activatedwith cytokines, including normal donor
pediatric cells (ND-P, n¼5). In red overexpressed
probe sets, in blue downregulated ones.
320Vector-derived b-globin synthesis provides correction of b/a
chains imbalance in erythroid cellsSince the imbalance between a- and b-globin chains is the
main cause of erythroid precursors death leading to
ineffective erythropoiesis and anaemia, the evaluation of
the newly synthesized globin chains provides the only
quantitative measurement of the correction of the b/a ratio.
Therefore, we performed reverse phase-HPLC analysis of
radiolabelled protein extracts from erythroid cultures at day
14. As reported in Fig 5, this analysis shows absence of
b-chain synthesis in b0 cells and low level of synthesis in 2010 EMBO Molecular Medicinebþ cells, resulting in a b/a ratio of 0.14. In these experiments,
the b/a ratio in control normal cells (ND1 and 2) is 0.97 and
0.79, respectively. Restoration of b-chain synthesis in
transduced b0 cells, revealed by the appearance of a distinct
peak in Fig 5 (lower left panel), results in a b/a ratio of 0.30.
Similarly, this value is increased up to 0.35 in genetically
modified bþ cells (Fig 5, right panels). Both these values are in
the range of those observed in b-thalassemia carriers
(Giordano et al, 1999), indicating that gene transfer with
GLOBE in thalassemic cells provides transgene expression at
therapeutic level.EMBO Mol Med 2, 315–328 www.embomolmed.org
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Figure 4. Transduction efficiency of thalassemia
major CD34R cells by GLOBE vector and correction
of HbA deficiency in transduced erythroblasts.
A. Schematic representation of the percentage of
transduction as determined by PCR on CFUs
derived from transduced CD34þ cells, and of the
average VCN/cell, as determined by qPCR on bulk
erythroid culture. Single dots and triangles
represent individual experiments.
B. Left: Representative FACS analysis for HbA
expression at 2 weeks of erythroid culture from
normal (ND1), thalassemic (THAL 106, 51) and
thalassemic GLOBE-transduced (THAL 106-
GLOBE, 51-GLOBE) CD34þ cells after
intracellular HbA staining. Right: Cumulative
data from FACS analysis for HbA expression in
erythroid cells. In the upper panel, the mean
proportion SEM of HbAþ cells in normal (ND,
black bar, n¼5), thalassemia-b0 (THAL-b0, white
bar, n¼7) and thalassemia-b0-GLOBE-trans-
duced (THAL-b0-GLOBE, grey bar, n¼7) cultures.
In the lower panel, the MFI of HbA-expressing
cells in the normal (ND, black bar, n¼5),
thalassemic (THAL-b0 and -bþ, white bars, n¼7
and 3) and thalassemic GLOBE-transduced
(THAL-b0 and -bþ, grey bars, n¼7 and 3)
cultures. Asterisks indicate parameters
significantly different between groups
(p<0.05; p<0.01; p< 0.001).
Figure 5. Reverse phase HPLC analysis of
radiolabelled globin chains synthetized in
erythroblastic culture.
HPLC profile of globin chains obtained from lysates
of 15106 erythroid cells after 14 days of liquide
culture started from normal (ND1 and ND2),
thalassemic (THAL 35¼ THAL-b0 and THAL
51¼ THAL-bþ) and thalassemic GLOBE-transduced
(THAL b0-GLOBE or THAL bþ-GLOBE) BM CD34þ cells
after metabolic incorporation of radiolabelled
leucine. Neo-synthetized single globin chains (a, b,
d, Ag and Gg) are indicated on each corresponding
peak.
www.embomolmed.org EMBO Mol Med 2, 315–328  2010 EMBO Molecular Medicine 321
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Figure 6. Correction of ineffective
erythropoiesis.
A. Photographs of May Gru¨nwald–
Giemsa-stained cytospin of erythroid
cells from normal donor (ND),
b-thalassemia (THAL) and GLOBE-
transduced b-thalassemia (THAL-
GLOBE) samples after 2 weeks of
erythroid liquid culture (Microscope:
Olympus Provis AX70. Objective: 100/
1.30 oil).
B. Percentage cell number for each
erythroblasts population after differ-
ential counting. ND n¼4, THAL n¼ 7,
THAL-GLOBE n¼7.
C. Representative FACS analysis of GpAþ
erythroid cells for apoptotic/dead cells
using Annexin V or propidium iodide
labelling. Percentage of double positive
cells on the total is reported in the
panel.
D. Percentage of apoptotic (GpAþ Annexin
Vþ) or late apoptotic/dead (GpAþ PIþ)
erythroid cells at day 14 of culture. ND
n¼ 2, THAL n¼3, THAL-GLOBE n¼ 3
THAL vs. THAL-GLOBE; p<0.05.
322Restoration of effective erythropoiesis by GLOBE-transduced
cellsDifferential counting of thalassemic cells at day 14 of the
erythroid culture shows a block in the differentiation, indicated
by reduced progression to the orthochromic normoblast stage
and increased cell death, occurring particularly at the stage of
polichromatophilic normoblast. In contrast, THAL-GLOBE cells
differentiate to orthochromic erythroblasts and eventually to
reticulocytes similarly to normal cells (Fig 6A). The relative
proportion of proerythroblasts, basophilic, polichromatophilic,
orthochromic normoblasts and reticulocytes in GLOBE-trans-
duced samples are comparable to those of normal samples
(1.0 0.6%, 5.5 1.6%, 17.3 3.6%, 60.1 4.4%, 6.9 3.3%
vs. 0.5 0.5%, 4.8 0.7%, 25.6 2.2%, 55.2 5.5%,
6.4 4.6%, respectively). In thalassemia major control samples 2010 EMBO Molecular Medicinethere are a high frequency of dead cells (21.7 4.4%), few
reticulocytes (0.4 0.2%) and a significantly reduced (p< 0.01)
proportion of late normoblasts (orthochromic, 44.8 6.3%)
with respect to both normal and transduced samples (Fig 6B).
According to these data, analysis of apoptosis and cell death in
thalassemic cultures reveals a high proportion of GpAþ cells co-
expressing the apoptotic marker Annexin-V (33.5 5.4%) and
stained positive after PI exposure (18.1 3.1%). Differently, the
frequency of apoptotic and late apoptotic/dead cells in
transduced samples is significantly reduced (17.3 3.1% and
8.9 2.9%, p< 0.05) and comparable to that observed in
normal control (13.80 0.5% and 7.6 1.6%) (Fig 6C and D).
These results indicate that thalassemic cells transduced with
GLOBE are able to overcome the arrest in erythroid maturation
and progress to normal erythropoiesis.EMBO Mol Med 2, 315–328 www.embomolmed.org
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Figure 7. Distribution of the GLOBE vector
integration sites in the human genome and
correlation with gene activity in CD34R cells.
A. GLOBE vector integration sites (red bars) in the
genome of BM-CD34þ cells from thalassemic
patients. LV-CMV-GFP integrations (LV-GFP) and
random genomic sequences originated by LM-
PCR (RANDOM), are used as control (green and
blue bars, respectively). Intergenic, intragenic
and TSS-proximal integrations are defined as
represented in the scheme. Asterisks indicate
frequency significantly different between groups
(p<0.05; p<0.001).
B. Distribution of target genes in the different
expression level categories. The first two bars
(CHIP THAL and CHIP CD34þ) show the
distribution of the genes on the microarray of
thalassemic and normal CD34þ cells activated
with cytokines, the third bar (RANDOM)
represents random control sequences, the fourth
and fifth bars (LV-GFP and GLOBE) report the
expression values of genes targeted by control
LV-CMV-GFP and GLOBE integrations,
respectively. The N-value indicates the number
of probesets, the n values indicate the number of
genes analysed.GLOBE integration preferences in CD34R cells from
thalassemic patientsTo gain insight on the integration preferences of the GLOBE
vector, we transduced 1 106 CD34þ cells from four thalasse-
mic patients at anMOI of 100, after 30 h of pre-stimulations with
cytokines, as described above. Cells were cultured for 14 days
(five to six cell doublings) to dilute unintegrated lentiviral
genomes, and vector-genome junctions cloned and sequenced
by linker-mediated (LM) PCR, as previously described (Catto-
glio et al, 2007). No cell selection was expected to occur in this
short culture period. A total of 403 unique integration sites (106
from THAL 20, 136 from THAL 37, 38 from THAL-40 and 123
from THAL 41; Table S2 of Supporting Information) were
mapped on the human genome and annotated as intergenic,
intragenic and transcription start site (TSS) proximal as
indicated in Fig 7A. A collection of 438 integration sites of a
LV expressing green fluorescent protein (GFP) under a CMV
promoter (Felice et al, 2009) and of 385 random control
sequences (Cattoglio et al, 2007) were used as comparison. The
overall distribution of GLOBE and CMV-GFP integrations
showed the same over-representation of intragenic (57.3% vs.www.embomolmed.org EMBO Mol Med 2, 315–32858.9%, p> 0.05) and under-representation of intergenic (32.0%
vs. 31.8%, p> 0.05) sites compared to the random controls
(35.1% intragenic and 59.5% intergenic, p< 0.001 in all
comparisons), which essentially reflect the gene content of
the human genome (Fig 7A). For both vectors, TSS-proximal
integrations were only slightly over-represented compared to
random controls (10.9 and 9.1% vs. 5.5%, p< 0.01 and p> 0.05,
respectively). Importantly, GLOBE showed the same low
tendency of CMV-GFP to integrate at recurrent sites (hot spots)
in the CD34þ cell genome (6.4% vs. 5.9%, p> 0.05), identifying
12 hot spots in both cases (Table S3 of Supporting Information).
Hot spots were defined according to standard criteria, i.e. at least
two integrations in <30 kb, three in <50 kb and four in <100 kb
(Wu et al, 2006). It is worth noting that 1.6% of random sites
met the same criteria (three hot spots), defining a background
level of false positivity. The hot spots lists contain three cancer-
related genes for GLOBE (NBN,NF1 and RFX2) and one for CMV-
GFP (UHRF2) and random controls (ESR1). Although these
numbers are too small to draw statistically significant conclu-
sions, there appears to be no tendency for either LV to integrate
into proto-oncogenes, as observed for retroviral vectors derived 2010 EMBO Molecular Medicine 323
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324from the Moloney murine leukaemia virus (Cattoglio et al,
2007).
To correlate vector integration with gene activity, we
determined the expression level of all genes located in an
arbitrary 60-kb window around each GLOBE, CMV-GFP and
random integration site. For this analysis, we used Affymetrix
expression profiles of CD34þ cells isolated from three different
thalassemic patients (for GLOBE integration sites) or from three
normal donors (for LV-GFP and random sites) and activated in
culture in the same conditions used for transduction. Average
gene expression values were divided in four classes, i.e. absent,
low, intermediate and high (seeMaterials andMethods Section).
The analysis showed that the GLOBE vector integrates
preferentially within or close to genes active in CD34þ cells
at the time of transduction (73%), with a significant over-
representation compared to random controls (60.2%, p< 0.001)
or to the overall distribution of gene expression values in
thalassemic CD34þ cells (53.1%, p< 0.001) (Fig 7B). The
control LV-GFP vector showed a virtually identical preference
for expressed genes (75.4% vs. 72.5%, p> 0.05) and a very
similar distribution in the four gene expression classes, with no
specific preference for highly expressed genes (16.2% vs.
17.8%, p> 0.05). Overall, these results indicate that the
presence of b-globin transcriptional regulatory elements in
the GLOBE vector does not influence its general integration
preferences when compared to a conventional SIN-LV vector.DISCUSSION
The development of HIV-derived vectors and the optimization of
HSC transduction conditions has provided a significant
contribution to the field of gene therapy for b-thalassemia,
leading to the application of LVs expressing the human b-globin
gene in preclinical murine models and in human thalassemic
cells (Malik et al, 2005; Sadelain et al, 2007). The unique feature
of b-globin LVs, carrying the transgene expressed by a
combination of large regulatory elements derived from the
globin locus, greatly affects the production of high-titer viral
stocks and the transduction efficiency of target cells. Moreover,
a delicate balance must be achieved to reconcile the needs for
high efficiency of transduction of a considerable number of
stem/progenitor cells, obtainable by cytokine-mediated stimu-
lation and expansion and the maintenance of their biological
features. Therefore, the characterization of transduced cells is
crucial to predict a favourable outcome of the overall procedure.
We characterized the BM-derived CD34þ cell population, which
represents the preferential target of gene therapy clinical trials
for genetic diseases involving children (Aiuti et al, 2009; Gaspar
et al, 2004; Hacein-Bey-Abina et al, 2002), by analyzing the
phenotype, clonogenic capacity and changes induced by the
transduction procedure. BM will represent the most suitable
source of haematopoietic progenitors for autologous transplan-
tation in pediatric thalassemic patients in future gene therapy
trials. Indeed, BM harvest is a safe procedure in children
(Buckner et al, 1984), while cytokine-mobilization in thalasse-
mic patients poses some safety concerns, due to the chronic 2010 EMBO Molecular Medicinehypercoagulable state (Taher et al, 2008) and the condition of
splenomegaly often associated with the disease. We found that
the frequency of multipotent progenitors and lineage-committed
precursors in thalassemic BM is comparable to that in normal
samples, and is not affected by the transduction procedure. The
phenotype analysis for expression of surface markers char-
acterizing the multipotent, common lymphoid and myeloid
progenitors reveals that short exposure to cytokines, present in
the preactivation/transduction medium, favours the expansion
of the myeloid subpopulation against the lymphoid one.
Experiments in normal donor samples give comparable results
and the change in the relative proportion of committed
progenitors is not reflecting a significant alteration in the
number and quality of early progenitors, scored by clonogenic
assay. Considering that, in the setting of gene therapy, the
haematopoietic reconstitution will occur in the absence of
immunosuppression, a decreased number of lymphoid pro-
genitors in the transplant is not likely to compromise the
outcome. Indeed, no evidence of immunological failure was
reported in gene therapy clinical trials for genetic diseases.
Moreover, in the presence of stressed erythropoiesis and
erythroid expansion, like in thalassemia major BM, it is relevant
to test the proportion of erythroid committed progenitors.
Differently from previous results (Mathias et al, 2000), by
analyzing a large number of samples we show normal
expression of the erythroid differentiation markers and
clonogenicity. Differences in patients’ age and clinical status
at the time of marrow harvest could explain these findings.
Moreover, gene expression profiling of cytokine-treated and -
untreated CD34þ cells suggests that the effect of the transduction
is similar between patients and healthy donors. Nevertheless,
the nature of specific genes that are differentially expressed
upon cytokine treatment might suggest a specific reponse in
thalassemic cells. Indeed, analysis of specific pathways relevant
for HSC biology and activity is in progress. However, the best
prediction for repopulating activity of human cells comes from
transplantation of high number of CD34þ cells in immunodefi-
cient mice. The source of cells for this kind of experiment would
come only from back-up, harvested from patients before
transplantation, and we are planning these experiments for
the future.
Recently, we achieved long-term correction of thalassemia in
the th3 murine model using the novel GLOBE vector (Miccio et
al, 2008). Following on from this successful result, the
exploitation of the therapeutic efficacy of GLOBE was
investigated in BM-derived CD34þ cells. We have shown
correction of hallmark features of the b-thalassemia phenotype,
such as synthesis of HbA and ineffective erythropoiesis.
Analyses of erythroid cultures demonstrate that GLOBE is able
to efficiently transduce CD34þ cells, providing physiological
levels of HbA in the erythroid progeny with a relatively low
number of integrants per cell, in line with our results in the
murine model (Miccio et al, 2008). The beneficial effect of
transgene expression results in the increased proportion of
mature erythroblasts in comparison to untransduced controls.
Importantly, HPLC analysis of newly synthesized globin chains
reveals that a/b chain ratio is in the range of that reported inEMBO Mol Med 2, 315–328 www.embomolmed.org
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et al, 1999), indicating that gene transfer with GLOBE provides
transgene expression at therapeutic level. Successful results in
patients’ cells were previously achieved by transduction with a
b-globin LV contained almost all LCR sites (HS 2, 3 and 4), in
addition to the 30 enhancer and the 1.2 kb cHS4 insulator
(Puthenveetil et al, 2004). However, as reported in recent
studies, large insulator elements negatively affect vector titer
and stability of viral particles, thus limiting the scale-up
production for clinical application (Hanawa et al, 2009; Urbinati
et al, 2009). Recent work on smaller sequences from cHS4 gave
promising results in murine cells (Arumugam et al, 2009). So
far, efficacy data obtained with GLOBE in a large and
heterogenous group of patients’ samples strengthen the
therapeutic potential of transcriptionally regulated globin LVs
for future clinical application.
An important issue to address is the prediction of the safety of
a gene therapy approach (Nienhuis et al, 2006). In contrast to
RVs, LVs appear to integrate in the host genome throughout the
transcriptional unit without preference for TSSs or promoters
(Bushman et al, 2005), and are therefore associated to a lower
risk of insertional activation of cellular genes by transcriptional
mechanisms. Data from the first trial using LV in two patients
affected by adrenoleukodystrophy are reassuring in terms of
safety, with no evidence of expansion of specific transduced
clones (Cartier et al, 2009). Moreover, vectors carrying b-globin
promoters and LCR elements restrict transgene expression to the
differentiated progeny within a single lineage, thereby reducing
the risk of activating oncogenes in haematopoietic stem and
progenitor cells. Our integration site analysis shows that GLOBE
has integration preferences virtually indistinguishable from
those of any other LV. GLOBE integration sites were associated
with transcriptionally active genes, evenly distributed among
low to high expression categories. Integrations hot spots are less
frequent compared to RVs, and cancer-related genes do not
appear to be over-represented compared to controls. We found
that most of the target genes are maintained transcriptionally
active in the genome of differentiating erythroblasts at day 7 and
day 14 (unpublished results). Overall, these findings suggest the
presence of a favourable chromatin context for transgene
expression around GLOBE integration sites and no specific risk
for the GLOBE vector. Notably, it was recently published that the
epigenetic changes in the transgene promoter can be modulated
by the presence of insulator elements in the vector (Arumugam
et al, 2009), thus representing a tool for further improvement of
transgene expression.
In conclusion, our results demonstrate the efficacy of a gene
therapy approach for b-thalassemia by transduction of human
progenitor cells with GLOBE vector and set the basis for a future
clinical trial.MATERIALS AND METHODS
Human subjects
Patients affected by thalassemia major or transfusion-dependent
thalassemia intermedia were enrolled in the BMT programmes at H.S.www.embomolmed.org EMBO Mol Med 2, 315–328Raffaele and IME Foundation. The diagnosis was based on family
history, transfusion dependence, analysis of globin chains synthesis by
HPLC and molecular analysis of mutations. BM aspirates performed for
the clinical purposes of pre-transplant marrow evaluation were
collected, following an hypertransfusion regimen, under general
anesthesia. BM and blood samples (5–10ml) were obtained from
32 patients at HSR and 12 patients at IME Foundation (age range
2–15 years). Normal CD34þ cells were either isolated from BM of
healthy individuals or purchased from Lonza Inc (Walkersville, MD). All
samples were obtained after informed consent from patients or legal
guardians and with the approval of Institutional Ethical Committees.
Genetic screening for globin mutations
Genomic DNA was isolated from peripheral blood leukocytes using the
Gentra Puregene Blood Kit (Qiagen). Characterization of mutations
was performed by DNA sequencing of the b-globin gene on the ABI
Prism 310 Genetic Analyzer (PE Applied Biosystems).
Isolation and characterization of BM-CD34R cells
Mononuclear cells were isolated from BM aspirates by Ficoll density
separation and CD34þ cells were selected using anti-CD34 microbeads
(Miltenyi Biotech). CD34þ cells labelled with fluorescein isothiocyanate
(FITC) or phycoerythrin (PE)-coniugated anti-CD34 antibodies (BD
Biosciences—Pharmingen) were analysed for the expression of other
markers using the following antibodies: PE-conjugated anti-GpA
(DakoCytomation), anti-CD71 (Immunotech), anti-CD33 (CALTAG),
FITC-conjugated anti-CD36, anti-CD50 (BD Biosciences—Pharmingen),
anti-CD10 and tri-color anti-CD38 (CALTAG). Analyses by FACS were
performed using FACSCanto flow cytometer (Becton Dickinson).
CFU assay
CD34þ cells were plated at 1103 cells/ml in methylcellulose
medium (GFH4434, Stem Cell Technologies). BFU-E, CFU-GM and
CFU-GEMM colonies were scored after 14 days.
Virus production
Viral stocks were produced and titered as described (Miccio et al,
2008) by transduction of HEL cells with serial dilution of vector stocks
followed by qPCR after 3 weeks of culture to allow dilution of
unintegrated vector below detection level. VCN/cell was measured by
qPCR on genomic DNA, using primers and probe annealing to RRE
region: forward primer 50-TGAAAGCGAAAGGGAAACCA-30 , reverse pri-
mer 50-CCGTGCGCGCTTCAG-30 and probe 50-VIC-AGCTCTCTCGACG-
CAGGACTCGGC-MGB-30 . Titers were espressed as transforming units
(TU)/ml and calculated multiplying the VCN/cell to the number of
transduced cells and then dividing for the viral vector dilution. Vector
particle was measured by HIV-1 gag p24 test (NEN Life Science
Products) and vector infectivity was calculated as the ratio between
titer and vector particle.
Transduction of human CD34R cells
CD34þ cells were seeded at 0.5–1106 cells/ml and pre-stimulated
for 30 h in CellGro medium (CellGenix) supplemented with 300 ng/ml,
human stem cell factor (hSCF) 300ng/ml, human Flt3-ligand (hFlt3-l), 2010 EMBO Molecular Medicine 325
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The paper explained
PROBLEM:
b-Thalassemia major or Cooley’s anaemia, leads to a profound
anaemia and to death in the first year of life, unless regular
transfusions are administered. So far, allogeneic bone marrow
transplantation (BMT) from HLA-matched donors is the only
curative treatment, but it is limited to less than 25% of patients.
Gene therapy, based on autologous transplantation of genetically
corrected hematopoietic stem cells (HSCs), represents a promising
alternative forpatients lackingasuitabledonor.Wehavepreviously
developedalentivirusvector(LV),GLOBE,codingfor thehumanbeta
globingeneand showed that transplantationofGLOBE-transduced
HSCs corrects thalassemia in murine models. To translate these
results into the clinics, it is now essential to demonstrate the
feasibility, safety and therapeutic efficacy of this approach by
testing the GLOBE LV in the context of human thalassemic cells.
RESULTS:
CD34þ cells purified from BM aspirates of thalassemia major
patients were transducedwith GLOBE and induced to differentiate
to the erythroblastic lineage. The procedure restored haemo-
globin production and erythropoiesis overcoming the
b-thalassemia phenotype. We sequenced andmapped the GLOBE
integration sites in the human cells to assess the risk of
integration in potentially dangerous loci and showed that GLOBE
integrates at low copy number into the human genome without
preferential targeting of proto-oncogenes, tumor-supressor or
cell cycle related genes.
IMPACT:
This study provides solid preclinical data of efficacy and safety of
the GLOBE-based gene therapy approach to b-thalassemia for its
future clinical translation in the context of an acceptable risk/
benefit ratio.
326100 ng/ml human trombopoietin (hTPO) and 60 ng/ml human
Interleukin-3 (hIL-3) (all PeproTech) on plates coated with retronectin
(Takara Shuzo). Transduction was performed overnight at multiplicity
of infection (MOI) of 50–100 and at a viral concentration of
5107 trasforming units (TU)/ml.
Erythroid liquid culture
CD34þ cells were cultured for 14 days using a procedure modified
from previous reports (Giarratana et al, 2005; Migliaccio et al, 2002).
The cells were seeded at 105 cells/ml in StemSpan medium (Stem Cell
Technologies) containing 20% foetal bovine serum (FBS) (Hyclone) and
supplemented with hSCF (10ng/ml), human erythropoietin (Epo)
(1U/ml), hIL-3 (1 ng/ml), 10–6M dexamethasone (Sigma) and 10–6M
b-estradiol (Sigma). At day 8, cells were grown in medium with 10%
FBS and 2U/ml Epo, and at day 11 they were cultured with 10% FBS
only. Globin production was tested by FACS and HPLC analysis.
Differential counting was performed on cells stained with May
Gru¨nwald–Giemsa reagent. Apoptotic and dead cells were revealed by
flow cytometry using the Apoptosis Detection Kit I (BD).
Analysis of HbA and globin chains production
The proportion of erythroid cells expressing HbA was assessed by flow
cytometry as described (Bohmer, 2001). 15106 cells from erythroid
cultures were incubated for 1 h in 3H-leucine (Perkin Elmer) in
depleted Dulbecco’s Modified Eagle medium (DMEM) (MP Biomedi-
cals) and lysed for reverse phase-HPLC analysis (Galanello et al, 1998).
DNA analysis
Genomic DNA was extracted using the QIAmp DNA mini Kit (Quiagen)
or the ChargeSwitch Forensic DNA Purification Kit (Invitrogen) and the 2010 EMBO Molecular Medicineaverage VCN/cell was measured as described (Miccio et al, 2008).
Transduction efficiency was determined by PCR on CFUs, amplifying
the HS2-HS3 sequence (forward primer HS2F 50-GTTGGAGGATACC-
CATTCTCTATCT-30 and reverse primer HS3R 50-TGGGTCAGTGGTCT-
CAATGTAGCA-30; PRIMM, Italy).
Sequencing and mapping of integration sites
CD34þ cells were transduced with GLOBE and cultured for 14 days to
dilute unintegrated vector. Integration sites were cloned as described
(Cattoglio et al, 2007) and mapped onto the human genome (UCSC
HG18, Mar.2006) using BLAT requiring a 95% identity. Sequences
were annotated as reported (Felice et al, 2009). A genomic region was
defined as a ‘hot spot’ for integration according to criteria developed
for defining cancer-related common integration sites (CISs) with minor
modifications (Cattoglio et al, 2007). We classified cancer-related
genes referring to the Upenn databases (http://microb230.med.upen-
n.edu/protocols/cancergenes.html).
Gene expression profiling and microarray analysis
Transcriptional profiling was determined in 42 samples of BM-derived
CD34þ cells, using Affymetrix HG-U133 Plus 2.0 GeneChip arrays. RNA
was isolated using RNeasy Plus Mini kit (Quiagen). Two-cycle target
labelling assays, Affymetrix HG-U133 Plus 2.0 GeneChip arrays
hybridization, staining and scanning, were performed using Affymetrix
standard protocols (Affymetrix, Santa Clara, CA). Fluorescence signals
were recorded by an Affymetrix scanner 3000 and image analysis
performed with the GeneChip Operating Software (GCOS) software.
Preprocessing of the data and normalization was carried out in
R (‘Affy’ package), unsupervised hierarchical clustering in dCHIP
(Li & Wong, 2001) and supervised ANOVA with the Partec GenomicEMBO Mol Med 2, 315–328 www.embomolmed.org
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isolated from three samples of cord blood derived-CD34þ cells
activated with cytokines. The raw gene expression data are available
at http://www.ebi.ac.uk/microarray (Accession #E-MEXP-2757 and
E-MEXP-2758).
To correlate vector integration and gene activity the arrays generated
from patients’ cells (THAL 22, 36, 37) and three healthy donors,
activated by cytokines, we re-annotated the Affymetrix HG-U133 plus
2.0 probe sets with custom CDF files to include only probes
unequivocally matching a transcript (Dai et al, 2005; Ferrari et al,
2007). The average of the expression values in each triplicate was
considered. Expression values from microarrays were combined and
divided into four classes, as absent, low (below the 25th percentile in a
normalized distribution), intermediate (between the 25th and 75th
percentile) and high (above the 75th percentile).
Statistical analyses
We used paired two-tailed t-tests for the comparisons of samples
before and after transduction and unpaired two-tailed t-tests to
compare other population means. All these statistical analyses were
performed using GraphPad Prism Version 4.0b (GraphPad Software,
San Diego, USA). For pairwise comparisons in integration analysis,
we applied a 2-sample test for equality of proportions with continuity
correction using the Rweb 1.03 statistical analysis package. To search
for gene differentially expressed in normal and thalassemic samples,
we used a one-way analysis of variance with a pre-set fold change of
>1, followed by Bonferroni correction for false discovery rate at a level
of significance of 0.05.Author contributions
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